| Response measure | Family history of RA | Family history of infl. arthritis | Family history of SLE | Family history of CTD | |||||
|---|---|---|---|---|---|---|---|---|---|
| No | Yes | Adj. OR (95%CI) | Yes | Adj. OR (95%CI) | Yes | Adj. OR (95%CI) | Yes | Adj. OR (95%CI) | |
| Switched treatment | 12% | 14% | 1.2 (1.0–1.6) | 13% | 1.1 (0.6–1.8) | 8% | 0.6 (0.2–1.7) | 17% | 1.4 (0.7–2.7) |
| No response | 20% | 20% | 1.1 (0.9–1.4) | 19% | 1.0 (0.6–1.6) | 20% | 0.9 (0.4–2.0) | 20% | 1.1 (0.6–2.0) |
| Moderate response | 29% | 28% | 1.1 (0.9–1.3) | 30% | 1.2 (0.8–1.8) | 26% | 0.8 (0.4–1.6) | 24% | 0.8 (0.5–1.5) |
| Good response | 39% | 37% | Ref. | 39% | Ref. | 46% | Ref. | 39% | Ref. |
| On TNFi at 5 (±3) months | Adj. mean dif. (95%CI) | Adj. mean dif. (95%CI) | Adj. mean dif. (95%CI) | Adj. mean dif. (95% CI) | |||||
| ΔVAS Pain | −24.2 | −24.1 | −0.1 (−2.4–2.1) | −21.4 | 2.3 (−2.4–7.1) | −23.5 | 1.3 (−6.7–9.3) | −21.2 | 2.7 (−4.2–9.6) |
| ΔHAQ | −0.3 | −0.3 | −0.0 (−0.0–0.0) | −0.3 | 0.0 (−0.1–0.1) | −0.3 | 0.0 (−0.1–0.1) | −0.3 | −0.0 (−0.2–0.1) |
| ΔESR | −10.5 | −9.6 | 0.4 (−1.2–1.9) | −6.9 | 2.6 (−0.6–5.8) | −5.4 | 5.3 (−0.2–10.9) | −11.6 | −1.6 (−6.3–3.0) |
| ΔDAS28 | 1.7 | 1.6 | −0.0 (−0.2–0.1) | 1.7 | 0.0 (−0.2–0.3) | 1.6 | −0.1 (−0.5–0.4) | 1.6 | −0.1 (−0.4–0.3) |
| ΔTJC | −5.0 | −4.6 | 0.2 (−0.2–0.7) | −5.2 | −0.5 (−1.5–0.5) | −5.0 | −0.2 (−1.9–1.6) | −4.8 | 0.0 (−1.4–1.5) |
| ΔSJC | −5.4 | −5.3 | −0.1 (−0.5–0.3) | −5.2 | −0.2 (−1.1–0.7) | −5.6 | −0.2 (−1.7–1.3) | −5.4 | −0.2 (−1.4–1.1) |
| ΔCRP | −12.6 | −11.1 | 0.6 (−1.7–2.8) | −8.1 | 2.7 (−2.2–7.6) | −7.3 | 5.7 (−2.4–13.8) | −16.9 | −4.9 (−11.9–2.0) |
| ΔGH | −24.6 | −23.7 | 0.7 (−1.5–2.9) | −23.3 | 0.6 (−4.1–5.4) | −27.5 | −2.4 (−10.4–5.5) | −23.2 | 0.7 (−6.2–7.5) |
Notes: Adj. for baseline dif. in sex, age, birth year and symptom duration.